Esperion Therapeutics (ESPR)
(Real Time Quote from BATS)
$2.40 USD
+0.04 (1.70%)
Updated Jul 5, 2024 02:20 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
Brokerage Reports
0 items in cart
Esperion Therapeutics, Inc. [ESPR]
Reports for Purchase
Showing records 21 - 40 ( 158 total )
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Litigation Out, Cash In; Focus Solely On Timely E.U. Commercialization
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
FDA Taking Actions Ahead of CV Risk Reduction Label Expansions
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Three Near-Term PDUFAs Should Drive Significant Long-Time Coming Value
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
BDA Fully Engaged in TRANSFORMing CVD; Global Label Expansions Expected in 1H24
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
3Q23 Results; BDA on Track For Global Label Expansion; U.S. PDUFA at March 31, 2024; Potential EMA Approval in 1H24
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department